{"id":"NCT01621802","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-21","primaryCompletion":"2015-07-06","completion":"2015-11-09","firstPosted":"2012-06-18","resultsPosted":"2017-09-13","lastUpdate":"2019-11-25"},"enrollment":4011,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Measles-Mumps-Rubella"],"interventions":[{"type":"BIOLOGICAL","name":"Priorix","otherNames":[]},{"type":"BIOLOGICAL","name":"M-M-R II","otherNames":[]},{"type":"BIOLOGICAL","name":"Kinrix","otherNames":[]},{"type":"BIOLOGICAL","name":"ProQuad","otherNames":[]}],"arms":[{"label":"Inv _MMR_CO Group","type":"EXPERIMENTAL"},{"label":"Com_MMR_CO Group","type":"ACTIVE_COMPARATOR"},{"label":"Inv_MMR_I Group","type":"EXPERIMENTAL"},{"label":"Com_MMR_I Group","type":"ACTIVE_COMPARATOR"},{"label":"Inv _MMR_S Group","type":"EXPERIMENTAL"},{"label":"Com_MMR_S Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when given as a second dose to children four to six years of age.","primaryOutcome":{"measure":"Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value","timeFrame":"42 days post vaccination (At Day 42)","effectByArm":[{"arm":"Inv_MMR_CO Group","deltaMin":697,"sd":null},{"arm":"Com_MMR_CO Group","deltaMin":249,"sd":null},{"arm":"Inv_MMR_I Group","deltaMin":736,"sd":null},{"arm":"Com_MMR_I Group","deltaMin":281,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":24},"locations":{"siteCount":67,"countries":["United States","South Korea","Taiwan"]},"refs":{"pmids":["30785357"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":802},"commonTop":["Injection site pain","Pyrexia","Injection site erythema","Injection site swelling","Nasopharyngitis"]}}